ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C15H22FN3O6
CAS番号:
分子量:
359.35
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
capecitabine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
O[C@H]1[C@@H](O)[C@H](N2C(N=C(NC(OCCCCC)=O)C(F)=C2)=O)O[C@@H]1C
InChI
1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
InChI key
GAGWJHPBXLXJQN-UORFTKCHSA-N
Gene Information
human ... TYMS(7298)
General description
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
Application
Capecitabine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
カペシタビンは抗癌剤（ドキシフルリジンのプロドラッグ）であり、腫瘍部位において代謝されて 5-フルオロウラシルを生成します。
カペシタビンは抗癌剤（ドキシフルリジンのプロドラッグ）であり、腫瘍部位において代謝されて 5-フルオロウラシルを生成します。カペシタビンは3段階の酵素反応と以下の2種類の中間代謝物を経由して活性化され、最終的に5-フルオロウラシルを生成します：5′-デオキシ-5-フルオロシチジン（5′-DFCR）および 5′-デオキシ-5-フルオロウリジン（5′-DFUR）。
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under カペシタビン
signalword
Danger
hcodes
pcodes
Hazard Classifications
Carc. 1B - Muta. 2 - Repr. 1B
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Francesco Giotta et al.
Tumori, 99(6), 278e-281e (2014-02-08)
We present the case of a 58-year-old woman with breast cancer metastasizing to the liver after adjuvant chemotherapy. A liver biopsy confirmed metastatic lesions from breast cancer that were immunohistochemically positive for estrogen/progesterone receptors and HER2. After first-line treatment with
Karen-Lise G Spindler et al.
Anticancer research, 34(2), 845-850 (2014-02-11)
We investigated the efficacy and safety of capecitabine and gemcitabin (GemCap) in heavily pre-treated, therapy-resistant metastatic colorectal cancer (mCRC) patients and the clinical importance of cell-free DNA (cfDNA) measurement. Patients' inclusion criteria included histopathologically-verified mCRC refractory to standard chemotherapy, adequate
Dermatomyositis associated with capecitabine in the setting of malignancy.
Frank W Chen et al.
Journal of the American Academy of Dermatology, 70(2), e47-e48 (2014-01-21)